<DOC>
	<DOCNO>NCT02779257</DOCNO>
	<brief_summary>Pasireotide bind somatostatin receptor sst2 sst5 , lead significant hyperglycemia . The investigator would like administer pasireotide treatment refractory hypoglycemia set metastatic insulin-producing pancreatic neuro-endocrine tumor .</brief_summary>
	<brief_title>Pasireotide Treatment Neuroendocrine Tumor</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Diazoxide</mesh_term>
	<criteria>1 . Aged 18 year old 2 . Biopsyproven ( primary metastatic lesion ) metastatic neuroendocrine tumor gastrointestinal pancreatic location disease determine CT scan MRI 3 . Patients history clinical syndrome symptom ( e.g . hypoglycemia ) 4 . Patients control treatment currently available somatostatin analogue . 5 . No evidence significant liver disease : Serum bilirubin ≤1.5 x ULN INR &lt; 1.3 ALT AST ≤ 3x ULN , Alkaline phosphatase ≤ 2.5 x ULN 6 . Written inform consent obtain prior treatment consistent local regulatory requirement 7 . Is suffer serious lifethreatening disease condition 8 . Does access comparable satisfactory alternative treatment ( i.e. , comparable satisfactory treatment available exist ) 9 . Is eligible participation IMP 's ongoing clinical trial recently complete clinical trial terminate , consider option ( e.g. , trial extension , amendment , etc . ) , clinical team determine treatment necessary feasible alternative patient 10 . Meets relevant medical criterion compassionate use investigational product 11 . Is transfer ongoing clinical trial still eligible 12 . There meaningful human clinical data support assessment potential benefit patient outweigh risk . 1 . Patients know hypersensitivity somatostatin analogs component pasireotide LAR s.c. formulation . 2 . Patients abnormal coagulation ( PT aPTT elevate 30 % normal limit ) . 3 . Patients continuous anticoagulation therapy . Patients anticoagulant therapy must complete washout period least 10 day confirm normal coagulation parameter study inclusion . 4 . Patients currently use warfarin / warfarin derivative 5 . Patients symptomatic cholelithiasis . 6 . Patients biochemically euthyroid . Patients known history hypothyroidism eligible adequate stable replacement thyroid hormone therapy least 3 month . 7 . QTrelated exclusion criterion : . QTcF screen &gt; 450 msec male , &gt; 460 msec female . Family history idiopathic sudden death Sustained clinically significant cardiac arrhythmia Risk factor Torsades de Pointes hypokalemia , hypomagnesemia , cardiac failure , clinically significant/symptomatic bradycardia , highgrade AV block Concomitant disease ( ) could prolong QT autonomic neuropathy ( cause diabetes , Parkinson 's disease ) , HIV , cirrhosis , uncontrolled hypothyroidism cardiac failure Family history long QT syndrome Concomitant medication know prolong QT interval . Potassium &lt; = 3.5 mmol/L 8 . Patients severe and/or uncontrolled medical condition : Uncontrolled diabetes define HbA1c &gt; 8 % Patients presence active suspect acute chronic uncontrolled infection history immunodeficiency , include positive HIV test result ( ELISA Western blot ) . An HIV test require ; however , previous medical history review . Nonmalignant medical illness uncontrolled whose control may jeopardize treatment study treatment . Lifethreatening autoimmune ischemic disorder . 9 . Patients history another primary malignancy , exception locally excise nonmelanoma skin cancer carcinoma situ uterine cervix . Patients evidence disease another primary cancer 1 year allow participate study . 10 . Patients history liver disease , cirrhosis chronic active hepatitis B C 11 . Presence Hepatitis B surface antigen ( HbsAg ) 12 . Presence Hepatitis C antibody ( antiHCV ) 13 . History , current alcohol misuse/abuse within past 12 month . 14 . Known gallbladder bile duct disease , acute chronic pancreatitis 15 . Patients hypomagnesaemia ( &lt; 0.7 mmol/L ) 16 . Patients history noncompliance medical regimen 17 . If patient sexually active male exclude unless agrees use condom intercourse take pasireotide 3 month stop pasireotide medication . They father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>hypoglycemia</keyword>
</DOC>